1151802-23-1

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-1-cyclopropyl-1H-pyrazole is used as a triazolopyridazine c-Met kinase inhibitor for the treatment of cancer. The compound targets the c-Met protein, which is a receptor tyrosine kinase involved in various cellular processes, including cell proliferation, migration, and survival. Overexpression or dysregulation of c-Met has been associated with the development and progression of several types of cancer. By inhibiting c-Met kinase activity, 4-bromo-1-cyclopropyl-1H-pyrazole may help in suppressing tumor growth and metastasis, offering a potential therapeutic strategy for cancer treatment.

Upstream product

• 1151814-36-6 1-cyclopropylpyrazole 
• 2075-45-8 4-bromo-1H-pyrazole 
• 4333-56-6 cyclopropyl bromide 
• 411235-57-9 cyclopropylboronic acid 

Downstream Products

• 1151802-22-0 1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1440965-10-5 3-chloro-6-(1-cyclopropyl-1H-pyrazol-4-yl)pyridazine 

Relevant academic research and scientific papers

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF

The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.